^
Association details:
| Biomarker: | TNFRSF8 negative |
|---|---|
| Cancer: | Peripheral T-cell Lymphoma |
| Drug: | Epidaza (chidamide) (HDAC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
COMPARISON OF CHIDAMIDE-CONTAINED TREATMENT MODALITIES VERSUS CHEMOTHERAPY IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Published date:
05/12/2021
Excerpt:
In the subgroup of CD30(-) patients, PFS was superior in the Chidamide+ChT group as compared with other groups (p =0.002, Figure 5)….first retreatment with chidamide+ChT regimen showed more PFS benefit than ChT and targeted therapy for RR PTCL patients, especially those with high second-line IPI, younger than 60 years and CD30(-).
Secondary therapy:
Chemotherapy